Prostate Cancer Clinical Trial

Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer

Summary

The purpose of this study is to examine the use of MRI surveillance for patients with no prostate cancer, potential prostate cancer, or diagnosed low-grade prostate cancer.

View Full Description

Full Description

This study will use MRI instead of prostate biopsy in combination with regularly scheduled urologist visits, interval PSA checks, and annual DRE to help establish a non-invasive method for 1) participants with a negative prostate MRI (PI-RADS 1 or 2) who have never had a biopsy; 2) participants with a positive MRI (PI-RADS score of 3, 4, or 5) and negative MRI-targeted biopsy pathology; and 3) monitoring participants with clinically diagnosed low risk prostate cancer who are on active surveillance. However, if at any point, clinical suspicion indicated either by the presence of suspicious lesions on the MRI, rising PSA, and/or positive DRE arises, then an immediate biopsy will be performed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Biopsy-naive patients with a negative prostate MRI (PI-RADS score 1 or 2); or
Patients with a PI-RADS score of 3, 4, or 5 on MRI and a negative MR-targeted biopsy; or
Patients on active surveillance with a negative prostate MRI (PI-RADS 1 or 2).

Exclusion Criteria:

Positive DRE;
PSA > 10 ng/ml or unstable PSA (doubling time <3 years) during the last year prior to enrolling in this study;
PSAD > 0.15 (calculated using most recent PSA divided by MRI prostate volume);
First degree relative diagnosed with prostate cancer
First degree relative diagnosed with a BRCA2 or Lynch syndrome associated gene causing any cancer.
Patient carries a mutation on BRCA2 or a mismatch repair gene associated with Lynch syndrome (MLHl, MSH2, MSH6, PMS2); known BRCA2 or known mismatch repair gene mutation in the family (Lynch Syndrome) and patient has not had testing; or family history consistent with BRCA2 or Lynch syndrome and there is no known BRCA2 or mismatch repair gene in the family.

Study is for people with:

Prostate Cancer

Study ID:

NCT03823001

Recruitment Status:

Withdrawn

Sponsor:

Case Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland Ohio, 44106, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Study ID:

NCT03823001

Recruitment Status:

Withdrawn

Sponsor:


Case Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.